Oxford Science Park based Sitryx aims to be a leader immunometabolism - a deal with Lilly has been validating

blonca9
Sep 17, 2024
1 min read

CEO Iain Kilty describes the keys to intervening in cell metabolism, and discusses pipeline assets such as a PKM2 for atopic dermatitis and a Lilly-partnered itaconate mimetic for autoimmune indications.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Oxford Science Park based Sitryx aims to be a leader immunometabolism - a deal with Lilly has been validating

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight